When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Abiraterone_acetate

   Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. [10] Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

3. STAMPEDE (clinical trial) - Wikipedia

   en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

   The overall conclusion was that "standard of care should be updated to include docetaxel chemotherapy in suitable patients with metastatic disease, and docetaxel may be considered for men with high-risk non-metastatic prostate cancer with or without radiotherapy". [5] Parker, James & Brawley 2018 reported on radiotherapy. For patients with a ...

4. J&J's Prostate Cancer Drug Zytiga Approved for Earlier ... - AOL

   www.aol.com/2013/01/11/jjs-prostate-cancer-drug...

   On Friday, Johnson & Johnson's Zytiga received an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer ...

5. How Johnson & Johnson Plans to Win the Prostate Cancer Battle

   www.aol.com/news/2013-09-26-how-johnson-johnson...

   J&J landed approval from the Food and Drug Administration for Zytiga as a treatment for metastatic castration-resistant prostate cancer, or mCRPC, in April 2011.

6. Niraparib/abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

   Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).

7. CYP17A1 inhibitor - Wikipedia

   en.wikipedia.org/wiki/CYP17A1_inhibitor

   CYP17A1 inhibitors, such as abiraterone acetate, are primarily used in the treatment of prostate cancer. These drugs reduce androgen levels, which helps to slow the progression of prostate cancer in patients with castration-resistant prostate cancer. [4]